18:56 , Jun 30, 2017 |  BC Week In Review  |  Clinical News

Boston Biomedical reports updated data from Phase Ib/II trial of amcasertib in solid tumors

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported updated data from 14 patients with advanced adenoid cystic carcinoma (ACC) in an expansion cohort of the Phase Ib/II BBI503-101 trial showing...
18:55 , Jun 30, 2017 |  BC Week In Review  |  Clinical News

Boston Biomedical reports Phase Ib/II data for Nexavar combos in HCC

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from 14 patients with hepatocellular carcinoma (HCC) in the Phase Ib/II BBI608-503-103HCC trial showing that twice-daily 160 or 240 mg oral...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

Amcasertib: Updated Phase I data

Updated data from 13 patients with adenoid cystic carcinoma (ACC) in an extension cohort of the open-label, North American Phase I BBI503-101 trial showed that once-daily 10-300 mg oral amcasertib led to a median PFS...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Amcasertib: Additional Phase I data

Data from 15 patients with squamous cell carcinoma of the head and neck (SCCHN) and 5 patients with parotid/salivary tumors in an extension cohort of the open-label, North American Phase I BBI503-101 trial showed that...
08:00 , Mar 8, 2010 |  BioCentury  |  Strategy

OSI Chronicles

OSI Chronicles Shares of OSI Pharmaceuticals Inc. jumped 139% to an all-time high of $91.10 in April 2004 when Tarceva erlotinib met the primary endpoint in a Phase III trial in non-small cell lung cancer...
08:00 , Mar 8, 2010 |  BioCentury  |  Strategy

OSI's Last Stand

OSI Pharmaceuticals Inc. has made two strategic decisions in the last five years that investors didn't like. As a result, it would not be surprising if they refuse to back the company's independence following last...
07:00 , May 29, 2006 |  BioCentury  |  Product Development

Informed optimism

Cancer immunotherapy has been in the doghouse of ideas for years, based on the failure of clinical trials too numerous to count. As a result, attitudes toward the concept have swung from unbridled enthusiasm to...
07:00 , Jun 14, 2004 |  BC Week In Review  |  Clinical News

Aptosyn exisulind: Phase III data

In a U.S. Phase III trial in 610 patients, Aptosyn plus Taxotere missed the primary endpoint of improving overall survival vs. Taxotere plus placebo. Median survival was 6.9 months for both treatment groups. The 1-year...
07:00 , Jun 11, 2004 |  BC Extra  |  Top Story

Aptosyn fails NSCLC Phase III

OSI (OSIP) said its Aptosyn exisulind plus Taxotere docetaxel missed the primary endpoint of improving overall survival versus Taxotere plus placebo in a Phase III trial in non-small cell lung cancer (NSCLC). Aptosyn also missed...
07:00 , Sep 15, 2003 |  BC Week In Review  |  Company News

Atrix management update

Atrix Laboratories Inc. (ATRX), Fort Collins, Colo.   Business: Drug delivery   Hired: Lloyd Glenn as VP of marketing and corporate development, formerly VP of sales and marketing at OSI Pharmaceuticals Inc. 's Cell Pathways...